PubMed Health⌕ Search

Biomedical subjects

M Recchia

Publications and source records attributed to M Recchia.

25 records · Page 2Linked to original sources
PubMed1975

Anatomical specificity as the critical determinant of the interrelationship between raphe lesions and morphine analgesia.

Electrolytic lesions were produced in three separate parts of the raphe mesencephalic area: the nucleus raphe medianus, the nucleus raphe dorsalis and an area between these two nuclei. Seven days after the surgery, the animals were tested for morphine analgesia using the tail compression method and then sacrificed for the estimation of brain serotonin. It was found that the analgesic effect of morphine was significantly reduced in the rats lesioned in the nucleus raphe medianus but not in the animals lesioned either in the nucleus raphe dorsalis or in the 'intermediate raphe area'. Since a decrease of forebrain serotonin was observed in each experimental group, the reduction of morphine analgesia does not involve a simple direct correlation with a decrease of serotonin in the forebrain. The results are discussed in view of the possibility that the reduction of morphine analgesia after lesions of the nucleus raphe medianus is due to a disruption of a specific brain serotonergic system.

Analgesia↗
PubMed1975

Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients.

Two preparations of carbamazepine, as tablets and in syrup, were given for 8 weeks to 20 patients with epilepsy in a randomized crossover study. Weekly plasma levels were 3-21 mg/1 on dosages of 5-24 mg/kg/day. There was no difference in absorption or steady-state level between the two preparations. Carbamazepine 10, 11-oxide was constantly present when the level of carbamazepine was over 5 mg/l, and tended to be lower with the syrup.

Administration, Oral↗
PubMed1975

Growth hormone secretion in chronic schizophrenia.

The GH response to insulin hypoglycemia (insulin 0.1 IU/kg i.v.) was studied under basal conditions and during a course of haloperidol therapy in 19 chronic schizophrenics, 15 hebephrenics and four paranoids (ten men and nine women, age 16--53 years). Haloperidol was given for 30 days, at a daily dose of 6 mg i.m., and the GH response to insulin-induced hypoglycemia was tested twice, before, and 10, 20, 30 days following the initiation of the treatment. The psychopathological features were controlled daily by two psychiatrists and by the ward staff and by the use of a Wittenborn rating scale, rated at the same intervals as the hormonal assays. From the results obtained it appears that in schizophrenic patients, GH secretion and response to insulin stimulus are extremely variable and are unaffected by haloperidol treatment. On the basis of the results obtained, the neurotransmitter-neurohormone regulation of GH secretion in schizophrenics is discussed.

Adolescent↗
PubMedDate not supplied

[Tiapride in the treatment of chronic headache (author's transl)].

The therapeutic efficacy of tiapride in chronic headache (300 mg/day orally during 30 days) was studied in a doubleblind trial in a group of 50 patients, 40 of them with so-called "mixed headache", and 10 with classical migraine. The results were subjected to statistical analysis. 65% of treated patients had clinical benefit in the intensity and frequency of headaches. The mode of action of this drug is discussed, together with the involvement of several monoaminergic systems in the genesis of headache. The action of tiapride appears to be indirectly dopaminomimetic as it operates by a blockade of dopaminergic inhibitors receptors.

Benzamides↗